Kodiak Sciences KOD
United StatesHealthcare · BiotechnologyUSD
116.67 USD (+28.1%)
6 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Kodiak Sciences is a clinical-stage biopharmaceutical company developing innovative therapies for retinal diseases, such as age-related macular degeneration, with a business model based on research and development of drugs.
Key points
from its scores- ✓Good share-price trend9.8
- ✕Little or no dividend0.5
- ✕Little competitive advantage0.8
- ✕Demanding valuation0.8
AI analysis
bottom line, main risk, context and newsHighly speculative investment: only suitable for investors with high risk tolerance and a long-term horizon, betting on the success of its clinical trials.
Kodiak Sciences is a clinical-stage biotech company with no revenue, a healthy balance sheet (net debt/EBITDA of 0.32) but very poor operational quality (ROE of -368%) and a valuation that reflects its high risk. The strong momentum of 177% suggests positive market expectations, but the lack of growth data and the speculative nature of the business make it a high-risk investment.
The main risk is the failure of its clinical trials or lack of regulatory approval, which could cause the company's value to plummet, given that it has no revenue or commercialized products.
Context and risks
Kodiak Sciences is a development-stage biotech with no revenue, an operating margin of 0%, and an ROE of -368%, reflecting a high-risk business model where value depends on clinical results and regulatory approvals. The moderate governance risk in the US sector and the speculative nature of the company justify a negative adjustment, although there are no specific news items to aggravate it.
Is Kodiak Sciences stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 93.5 | 4.1 | +2,176% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 116.67 USD, +28.1% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −26.5
- EV / EBITDA
- −24.4
- Price / book
- 93.5
- Market cap
- 5.7B USD
- Enterprise value
- 5.6B USD
Profitability
- ROE
- −368.4%
- ROA
- −60.4%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Free cash flow
- −58.4M USD
- FCF yield
- −1.0%
Solvency
- Total debt
- 52.8M USD
- Net debt
- −73.1M USD
- Cash
- 125.9M USD
- EBITDA
- −231.0M USD
- Net debt / EBITDA
- 0.32
- Debt / equity
- 86.35
- Current ratio
- 2.49
- Quick ratio
- 2.39
Growth
- EPS (TTM)
- −4.19 USD
- EPS (forward)
- −3.44 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 2.04
- Analyst consensus
- Strong buy (6)
- Target price
- 116.67 USD
- 52-week range
- 10.94 – 104.00
Recent news
All KOD news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Kodiak Sciences
Is Kodiak Sciences stock cheap or expensive?
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 116.67 USD, +28.1% versus the price. This is not investment advice.
What score does Kodiak Sciences get on MeridIAn Screener?
It scores 2.5 out of 10, rank 2,112 of 2,130 (better than 1% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Kodiak Sciences worth on the stock market?
Its market capitalisation is 5.7B USD and its enterprise value, debt included, is 5.6B USD.
How much debt does Kodiak Sciences have?
It has more cash than debt: net cash of 73.1M USD.
Does Kodiak Sciences pay a dividend?
It pays no dividend, or almost none.
How has Kodiak Sciences stock performed over the last year?
It has risen 667.3% over the last year, excluding dividends. Over the last 52 weeks it has traded between 10.94 and 104.00 USD. Past performance does not guarantee future results.
What do analysts think of Kodiak Sciences?
6 analysts cover it; their average recommendation is “Strong buy” and their average target is 116.67 USD (+28.1% versus the price). It is an estimate, not market data.